Skip to main content

Table 1 Summary of donor information

From: ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression

Study Cohorts:

Healthy Control

ALS

P value

Disease progression

 

Slow

Intermediate

Rapid

 

No. of participants

N = 20

N = 15

N = 6

N = 9

 

Sex of participants

  

 Females

55% (11/20)

33.3% (5/15)

66.7% (4/6)

44.4% (4/9)

0.46c+

 %, (proportion)

 Males

45% (9/20)

66.7% (10/15)

33.3% (2/6)

55.6% (5/9)

 %, (proportion)

Age: Mean (± SD)

65.3 (8.9)

57.2 (10.2)

70.3 (9.7)

66.0 (8.84)

0.40d+

Site of onset

    

 Bulbar: %, (proportion)

 

13.3% (2)

16.7% (1)

22.2% (2)

0.85c−

 Spinal: %, (proportion)

 

86.7% (13)

83.3% (5)

77.8% (7)

ALSFRS-Ra: mean, ± SD (range)

 

41.6, ± 3.4 (34–46)

41, ± 2.3 (38–44)

36.8, ± 5.04 (30–46)

0.02d−

ΔFSb: mean, ± SD (range)

 

0.25, ± 0.1 (0.1–0.45)

0.60, ± 0.1 (0.57–0.67)

1.72, 0.76 (1–3.4)

0.001d−

  1. aALSFRS-R (at diagnosis, when PBMCs were taken; normal score = 48)
  2. bDelta FS ratio (rate of disease progression); (48- ALSFRS-R score at time of diagnosis)/ time onset to diagnosis)
  3. SD Standard deviation
  4. ALSFRS-R Revised Amyotrophic Lateral Sclerosis Functional Rating Scale;
  5. cChi-square test
  6. dANOVA
  7. +p value for comparison between HC and ALS cohort
  8. p value for comparison between ALS subgroups